Evercore ISI Group Maintains Outperform on Insmed, Raises Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Josh Schimmer maintains an Outperform rating on Insmed (NASDAQ:INSM) and raises the price target from $32 to $42.
September 07, 2023 | 3:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evercore ISI Group maintains an Outperform rating on Insmed and raises the price target from $32 to $42.
The news is directly related to Insmed (INSM). The Outperform rating maintained by Evercore ISI Group and the increase in price target from $32 to $42 indicates a positive outlook for the company. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100